Skip Navigation

Your Environment. Your Health.

Immunogenetic Differences between Caucasian Women with & without Silicone Implants in whom Myositis Develops

Clinical Center, Maryland

Supplementary Table. Comparisons of clinical signs and symptoms, myositis autoantibodies and local complications associated with the use of silicone implants between MASI patients and matched IIM or SIC study groups

* Abbreviations per manuscript Table 1 and Jo-1, anti-histidyl tRNA synthetase; THR, anti-threonyl tRNA synthetase; ILE, anti-isoleucyl tRNA synthetase; Mi-2, anti-Mi-2; SRP, anti-signal recognition particle; LNE, lymph node enlargement. There were no significant differences (after correction for multiple comparisons) regarding these data among the groups.
**Serum was unavailable for 1 of 52 IIM patients.
Clinical Signs /
Symptoms
MASI,
n=26
n (%)
IIM,
n=52
n (%)
Fatigue 26 (100) 14 (26.9)
Weight Loss 11 (42.3) 19 (36.5)
Fatigue 26 (100) 47 (90.4)
Raynaud's Sign 11 (42.3) 25 (48.1)
Sjogren's Syndrome 15 (57.7) 19 (36.5)
Proximal Weakness 26 (100) 46 (88.5)
Distal Weakness 12 (46.2) 19 (36.5)
Asymmetric Weakness 5 (19.2) 14 (26.9)
Muscle Cramps 9 (34.6) 21 (40.4)
Arthralgias 19 (73.1) 24 (46.2)
Arthritis 14 (53.8) 19 (36.5)
Falling 5 (19.2) 13 (25.0)
Muscle Atrophy 6 (23.1) 19 (36.5)
Contractures 3 (11.5) 4 (7.7)
Carpel Tunnel 4 (15.4) 10 (19.2)
Dyspnea (EX) 16 (61.5) 20 (38.5)
Dyspnea (RE) 7 (26.9) 9 (17.3)
O2 Use 4 (15.4) 6 (11.2)
Changes Pulmonary Funct. 7 (26.9) 9 (17.3)
Interstitial Lung Disease 8 (30.8) 11 (21.2)
Cough 5 (19.2) 11 (21.2)
Chest Pain 2 (7.7) 5 (9.6)
Palpitation 5 (19.2) 15 (28.8)
Edema 13 (50.0) 16 (30.8)
Syncope 0 (0) 2 (3.8)
Dysphagia 12 (46.2) 24 (46.2)
Regurgitation 5 (19.2) 7 (13.5)
Diarrhea 2 (7.7) 6 (11.2)
Heliotrope Rash 9 (34.6) 19 (36.5)
V Sign Rash 5 (19.2) 10 (19.2)
Shawl Sign Rash 3 (11.5) 12 (23.1)
Gottron's Papules 10 (38.5) 17 (32.7)
Other Rashes 4 (15.4) 17 (32.7)
Mechanic's Hands 4 (15.4) 7 (13.5)
Nailbed Changes 4 (15.4) 6 (11.2)
Cuticular Overgrowth 3 (11.5) 6 (11.2)
Lymphadenopathy 3 (11.5) 1 (1.9)


Myositis-Specific
Autoantibodies
(MSA)
MASI,
n=26
n (%)
IIM,
n=51**
n (%)
MSA 8 (30.8) 22 (43.1)
Synthetase 5 (19.2) 18 (35.3)
Jo-1 3 (11.5) 14 (27.5)
THR 1 (3.8) 3 (5.9)
ILE 1 (3.8) 1 (2.0)
Mi-2 2 (7.7) 3 (5.9)
SRP 1 (3.8) 1 (2.0)


Myositis-Associated
Autoantibodies
(MAA)
MASI,
n=26
n (%)
IIM,
n=51**
n (%)
MAA 6 (23.1) 16 (31.4)
KU 0 (0) 0 (0)
LA 0 (0) 5 (9.8)
RO 3 (11.5) 6 (11.8)
PM/Scl 0 (0) 1 (2.0)
SM 0 (0) 2 (3.9)
RNP 3 (11.5) 2 (3.9)


Local
Complications
MASI,
n=26
n (%)
SIC,
n=52**
n (%)
Contracture 12 (46.2) 29 (55.8)
Rupture 8 (30.8) 18 (34.6)
Pain 6 (23.1) 11 (21.2)
Infection 3 (11.5) 5 (9.6)
Bleeding 0 (0) 7 (13.5)
Lumps/Asymmetry 7 (26.9) 9 (17.3)
LNE 4 (15.4) 8 (15.4)
Explants 17 (65.4) 28 (53.8)